Alembic Pharma gets USFDA nod for Parkinson's drug, boosts US generics presence

• Alembic Pharmaceuticals received final USFDA approval for its Carbidopa, Levodopa and Entacapone tablets on February 6.
• The approved tablets are a combination therapy for Parkinson's disease, therapeutically equivalent to Orion Corporation's Stalevo.
• This approval adds to Alembic's 234 cumulative ANDA approvals from the USFDA, including 214 final and 20 tentative approvals.
• The company reported a 10.8% revenue rise to ₹1,876.3 crore in the December quarter, with EBITDA up 12.8%.
• Net profit declined 4.1% to ₹132 crore due to a one-time ₹42 crore expense related to employee benefits.